IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
30 Maio 2023 - 9:04AM
Business Wire
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or
“IPA” or the “Company”), an AI-driven biotherapeutic research and
technology company, today announced that its subsidiary,
BioStrand®, has successfully solved the Information Integration
Dilemma (IID) by developing a unique technology design that enables
their patented HYFT Technology to encapsulate and unify diverse
data modalities - including syntactical (sequence) data, 3D
structural data, unstructured scientific information (e.g.
scientific literature), and beyond - into a singular, integrated
framework.
This breakthrough approach facilitates efficient data fusion,
enabling a comprehensive analysis and interpretation of complex
biological data. With HYFTs, BioStrand effectively addresses the
IID, paving the way for quicker and more potent biological
discoveries. This innovation has the potential to bring a paradigm
shift in various domains including drug development, biomarker
discovery, and the study of disease pathology, among others. The
IID has long been a significant challenge for the biotechnology
industry, as researchers and investors have grappled with the
complexities of integrating various data types to gain meaningful
insights. In the rapidly evolving field of biotechnology, data is
generated from multiple sources such as scientific literature,
experimental data, and genomic information. The integration of
these different data types is critical for accelerating innovation
and driving the discovery of novel therapeutics. However,
traditional approaches have struggled to efficiently combine and
analyze this diverse data, often leading to incomplete or
inaccurate conclusions. BioStrand's breakthrough approach leverages
its patented HYFT® technology and LENSaiTM platform, which together
enable the efficient analysis and understanding of complex
biological data. By solving the IID, BioStrand has unlocked new
possibilities for the discovery and development of novel
therapeutics, which is expected to benefit both patients and the
investor community.
Dirk Van Hyfte, Co-Founder and Head of Innovation of BioStrand,
said, "We are thrilled to have overcome the Information Integration
Dilemma, which has long been a major hurdle in our industry. Our
HYFT technology and LENSai platform are now poised to revolutionize
the way researchers and AI-driven systems process and analyze
complex biological data, ultimately leading to faster and more
effective drug discovery and development."
BioStrand's HYFT technology extracts unique patterns, known as
Universal Fingerprint™ patterns, from the entire biosphere, and
integrates them with various data sources, such as scientific
papers and medical records. The resulting Knowledge Graph
encompasses over 660 million HYFTs and more than 25 billion
relations, providing a powerful resource for researchers and
AI-driven analysis. The LENSai platform, powered by HYFT
technology, takes advantage of the latest advancements in large
language models (LLMs) to bridge the gap between syntax (sequences)
and semantics (functions). This enables the platform to extract
valuable insights from vast amounts of data, without the
limitations of traditional LLMs. IPA's support of BioStrand's
pioneering work reinforces its commitment to investing in
cutting-edge biotechnology solutions with the potential to
transform the industry. The successful resolution of the
Information Integration Dilemma not only demonstrates the
innovative nature of BioStrand's technology but also highlights the
Company's dedication to improving the lives of patients
worldwide.
About ImmunoPrecise Antibodies Ltd:
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modeling, and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome of integrating in silico models and wet-lab
experiments. In respect of the forward-looking information
contained herein, IPA has provided such statements and information
in reliance on certain assumptions that management believed to be
reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of in silico models and
wet-lab experiments may not have the expected results, as well as
those risks discussed in the Company’s Annual Information Form
dated July 28, 2022 (which may be viewed on the Company’s profile
at www.sedar.com), and the Company’s Form 40-F, dated July 29, 2022
(which may be viewed on the Company’s profile at www.sec.gov).
Should one or more of these risks or uncertainties materialize, or
should assumptions underlying the forward-looking statements prove
incorrect, actual results, performance, or achievements may vary
materially from those expressed or implied by the forward-looking
statements contained in this news release. Accordingly, readers
should not place undue reliance on forward-looking information
contained in this news release. The forward-looking statements
contained in this news release are made as of the date of this
release and, accordingly, are subject to change after such date.
The Company does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005237/en/
Investor: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024